ZURICH, March 4 Swiss stocks were expected to
open higher on Tuesday, mirroring other European bourses, as a
Russian decision to order troops in military exercises in
central and western Russia to return to base fanned hopes of a
The Swiss blue-chip SMI was seem rising 0.7 percent
to 8,336 points, according to premarket indications by bank
The following are some of the main factors expected to
affect Swiss stocks on Tuesday.
*GAM Holding AG reported underlying net profit of
210.2 million Swiss francs ($238.73 million)for 2013 and
proposed a dividend of 0.65 francs per share.
*Swissquote said net revenues rose 12 percent last
year to 124.9 million francs, helped by a rise in income from
forex trading and generating net profit of 11.7 million francs,
which was hit by one-off restructuring costs.
*Sika said sales rose 6.5 percent last year to
5.142 billion francs, generating net profit of 345 million
francs, up 23.8 percent. It forecast sales growth of 6-8 percent
this year assuming constant exchange rates and stable margin
*Feintool said sales rose 12 percent last year to
477 million francs generating an 11 percent increase in
operating profit to 24.5 million francs.
*Siegfried said sales rose by 2 percent to 375
million francs and net profit increased 21 percent to 54 million
*VZ Group said operating revenues rose 11.7 percent
to 171.1 million last year resulting in a net profit of 60
million francs. It expects revenues and profits to increase
further this year.
*Newron reported a net loss of 7.1 million euros
for 2013 due to lower license income and higher R&D investment.
*Ledermann Immobilien has sold a real estate package
to Swiss Life <SLHN.VX]. Details of the transaction price were
*ABB's Board of Directors will propose Hubertus
von Gruenberg for re-election as Chairman and Matti Alahuhta as
a new member of the board. All other members with the exception
of Hans Ulrich Maerki will stand for re-election.
*Lonza said its Board of Directors proposes
Barbara Richmond and Juergen Steinemann as new board members.
*Evolva reaches second milestone in Roquette
*Santhera Pharmaceuticals will present data from
its ongoing Expanded Access Program (EAP) with Raxone in the
treatment of Leber's Hereditary Optic Neuropathy at an upcoming
medical conference in Puerto Rico.
*Implenia said the project start on the Semmering
base tunnel has been postponed. It expects work will resume in
about six months.
($1 = 0.8805 Swiss francs)